Anemia in heart failure--a concise review.

Area of Science:

• Cardiology
• Hematology
• Pharmacology

Background:

• Heart failure affects millions, with increasing survival post-infarction leading to long-term remodeling and morbidity.
• Neurohormonal activation, particularly the renin-angiotensin system, plays a key role in heart failure progression.
• Anemia is a significant predictor of morbidity and mortality in heart failure patients.

Purpose of the Study:

• To describe the various causes of anemia in heart failure.
• To investigate the role of renin-angiotensin system (RAS) modulating drugs in anemia development.
• To highlight the impact of anemia as a modifiable risk factor in heart failure.

Main Methods:

• Review of current literature on heart failure, anemia, and RAS.
• Analysis of stem cell studies investigating erythropoiesis inhibition by RAS-acting drugs.
• Discussion of the physiological role of angiotensin-II and ACE in erythropoiesis.

Main Results:

• Drugs targeting the renin-angiotensin system (ACEIs, ARBs) may inhibit erythropoiesis.
• This inhibition can lead to anemia in patients with heart failure, regardless of renal function.
• Angiotensin-II acts as an erythropoietic growth factor, and ACE facilitates this process.

Conclusions:

• Anemia is a critical, modifiable risk factor in heart failure with significant prognostic implications.
• ACEIs and ARBs may contribute to anemia in heart failure patients by interfering with erythropoiesis.
• Further investigation into the etiology, impact, and treatment of anemia in heart failure is warranted.